Related references
Note: Only part of the references are listed.Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities
Priyatham S. Mettu et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2021)
Human umbilical cord mesenchymal stem cell-derived exosomal miR-27b attenuates subretinal fibrosis via suppressing epithelial-mesenchymal transition by targeting HOXC6
Dongli Li et al.
STEM CELL RESEARCH & THERAPY (2021)
Pharmacological Advances in the Treatment of Age-related Macular Degeneration
Maria Gil-Martinez et al.
CURRENT MEDICINAL CHEMISTRY (2020)
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Daniel F. Martin et al.
OPHTHALMOLOGY (2020)
Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis
Yanli Hou et al.
CANCER COMMUNICATIONS (2020)
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion A Randomized Clinical Trial
MinKe He et al.
JAMA ONCOLOGY (2019)
Sorafenib: key lessons from over 10 years of experience
Bernard Escudier et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2019)
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia
Maro Ohanian et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells
Alfeu Zanotto-Filho et al.
CANCER LETTERS (2018)
Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer
Cun Wang et al.
JOURNAL OF HEPATOLOGY (2018)
The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective
Freekje van Asten et al.
PLOS ONE (2018)
Intravitreal Injection of Hydrogen Peroxide Induces Acute Retinal Degeneration, Apoptosis, and Oxidative Stress in Mice
Bing Huang et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2018)
Light-Induced Lipocalin 2 Facilitates Cellular Apoptosis by Positively Regulating Reactive Oxygen Species/Bim Signaling in Retinal Degeneration
Wenyi Tang et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2018)
SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
Robert L. Avery et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2017)
A novel small molecule ameliorates ocular neovascularisation and synergises with anti-VEGF therapy
Rania S. Sulaiman et al.
SCIENTIFIC REPORTS (2016)
Intravitreal Injection of Proinsulin-Loaded Microspheres Delays Photoreceptor Cell Death and Vision Loss in the rd10 Mouse Model of Retinitis Pigmentosa
Carolina Isiegas et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2016)
Sorafenib for ovarian cancer
Umberto Leone Roberti Maggiore et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL
Bodvael Pennarun et al.
JOURNAL OF PATHOLOGY (2013)
Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice
Vincent Lambert et al.
NATURE PROTOCOLS (2013)
Photodynamic therapy for polypoidal choroidal vasculopathy
Patrycja Nowak-Sliwinska et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2013)
Sorafenib in melanoma
Joanna Mangana et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Sorafenib in non-small cell lung cancer
Jianjun Zhang et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGET
Thomas E. Hutson et al.
EUROPEAN JOURNAL OF CANCER (2010)
AKT signaling in regulating angiogenesis
Bing-Hua Jiang et al.
CURRENT CANCER DRUG TARGETS (2008)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
Share Paper
